CATALYST PHARMACEUTICALS, INC. (CPRX) Form 10-Q — May 11, 2026
Catalyst Pharmaceuticals, Inc. reported total revenues of $149.4 million for the three months ended March 31, 2026, a 5.6% increase from $141.4 million in the same period of 2025. The increase was primarily driven by higher sales volumes of FIRDAPSE® and AGAMREE®. The company's net income for the quarter was $63.7 million, or $0.52 per basic share, compared to $56.7 million, or $0.47 per basic share, in the same period of 2025.
Key figures
- Eps
- 0.52
- Revenue
- 149390
- Guidance
- The company believes it has sufficient funds to support operations for at least the next 12 months.
- Net Income
- 63734
- Total Debt
- 280
- Revenue Yoy
- 5.6
- Cash Position
- 755859
Price after filing
1 day: -0.0%7 days: +0.3%30 days: +0.6%
Close on the filing date to close N calendar days later (from $31.15). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.